The RAISE connection program: Psychopharmacological treatment of people with a first episode of schizophrenia

Psychiatric Services

Volumn 67, Issue 12, 2016, Pages 1300-1306

  Kreyenbuhl, Julie A ^a,b   Medoff, Deborah R ^a,b   McEvoy, Joseph P ^a   Smith, Thomas E ^d,e   Hackman, Ann L ^a   Nossel, Ilana R ^d,e   Dixon, Lisa B ^d,e   Essock, Susan M ^d,e   Buchanan, Robert W ^a,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d Columbia University College of Physicians and Surgeons ^*  (United States)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; FLUPHENAZINE DECANOATE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HALOPERIDOL; HALOPERIDOL DECANOATE; LIPID; LOXAPINE; LURASIDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; BENZODIAZEPINE DERIVATIVE;

ADULT; ARTICLE; BODY WEIGHT; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; METABOLIC DISORDER; OBSERVATIONAL STUDY; PRESCRIPTION; PROTOCOL COMPLIANCE; PSYCHIATRIST; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SIDE EFFECT; SIDE EFFECT ASSESSMENT; YOUNG ADULT; ADOLESCENT; CLINICAL PRACTICE; DECISION MAKING; DRUG ADMINISTRATION; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DECISION MAKING; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; PRACTICE PATTERNS, PHYSICIANS'; SCHIZOPHRENIA; UNITED STATES; YOUNG ADULT;

EID: 85000359867     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201500438     Document Type: Article

References (36)

1. Buchanan RW, Kreyenbuhl J, Kelly DL, et al: The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin 36:71-93, 2010
2. Lieberman JA, Phillips M, Gu H, et al: Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: A 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 28:995-1003, 2003
3. Schooler N, Rabinowitz J, Davidson M, et al: Risperidone and haloperidol in first-episode psychosis: A long-Term randomized trial. American Journal of Psychiatry 162:947-953, 2005
4. Robinson DG, Woerner MG, Napolitano B, et al: Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. American Journal of Psychiatry 163:2096-2102, 2006
5. Gaebel W, Riesbeck M, Wölwer W, et al: Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. Journal of Clinical Psychiatry 68:1763-1774, 2007
6. McEvoy JP, Lieberman JA, Perkins DO, et al: Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: A randomized, double-blind 52-week comparison. American Journal of Psychiatry 164:1050-1060, 2007
7. Kahn RS, Fleischhacker WW, Boter H, et al: Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet 371: 1085-1097, 2008
8. Sikich L, Frazier JA, McClellan J, et al: Double-blind comparison of first-And second-generation antipsychotics in early-onset schizophrenia and schizo-Affective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. American Journal of Psychiatry 165:1420-1431, 2008
9. Velligan DI, Weiden PJ, Sajatovic M, et al: The Expert Consensus Guideline Series: Adherence problems in patients with serious and persistent mental illness. Journal of Clinical Psychiatry 70(suppl 4):1-46, 2009
10. Robinson DG, Woerner MG, Alvir JMJ, et al: Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophrenia Research 57: 209-219, 2002
11. Kamali M, Kelly BD, Clarke M, et al: A prospective evaluation of adherence to medication in first episode schizophrenia. European Psychiatry 21:29-33, 2006
12. Perkins DO, Gu H, Weiden PJ, et al: Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: A randomized, double-blind, flexibledose, multicenter study. Journal of Clinical Psychiatry 69:106-113, 2008
13. Coldham EL, Addington J, Addington D: Medication adherence of individuals with a first episode of psychosis. Acta Psychiatrica Scandinavica 106:286-290, 2002
14. Subotnik KL, Nuechterlein KH, Ventura J, et al: Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. American Journal of Psychiatry 168:286-292, 2011
15. Mutsatsa SH, Joyce EM, Hutton SB, et al: Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatrica Scandinavica 108:439-446, 2003
16. Perkins DO, Johnson JL, Hamer RM, et al: Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophrenia Research 83:53-63, 2006
17. Adams JR, Drake RE: Shared decision-making and evidence-based practice. Community Mental Health Journal 42:87-105, 2006
18. Deegan PE, Drake RE: Shared decision making and medication management in the recovery process. Psychiatric Services 57: 1636-1639, 2006
19. Mistler LA, Drake RE: Shared decision making in antipsychotic management. Journal of Psychiatric Practice 14:333-344, 2008
20. Achieving the Promise: Transforming Mental Health Care in America. Pub no SMA-03-3832. Rockville, Md, Department of Health and Human Services, Presidents New Freedom Commission on Mental Health, 2003
21. Drake RE, Deegan PE, Rapp C: The promise of shared decision making in mental health. Psychiatric Rehabilitation Journal 34: 7-13, 2010
22. Kreyenbuhl J, Nossel IR, Dixon LB: Disengagement from mental health treatment among individuals with schizophrenia and strategies for facilitating connections to care: A review of the literature. Schizophrenia Bulletin 35:696-703, 2009
23. Dixon LB, Goldman HH, Bennett ME, et al: Implementing coordinated specialty care for early psychosis: The RAISE Connection Program. Psychiatric Services 66:691-698, 2015
24. Marino L, Nossel I, Choi JC, et al: The RAISE Connection Program for early psychosis: secondary outcomes and mediators and moderators of improvement. Journal of Nervous and Mental Disease 203:365-371, 2015
25. Essock SM, Nossel IR, McNamara K, et al: Practical monitoring of treatment fidelity: examples from a team-based intervention for people with early psychosis. Psychiatric Services 66:674-676, 2015
26. Essock SM, Goldman HH, Hogan MF, et al: State partnerships for first-episode psychosis services. Psychiatric Services 66:671-673, 2015
27. Herman D, Conover S, Felix A, et al: Critical Time Intervention: An empirically supported model for preventing homelessness in high risk groups. Journal of Primary Prevention 28:295-312, 2007
28. Subotnik KL, Casaus LR, Ventura J, et al: Long-Acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial. JAMA Psychiatry 72:822-829, 2015
29. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychological Reports 10:799-812, 1962
30. Andreasen NC: Negative symptoms in schizophrenia: definition and reliability. Archives of General Psychiatry 39:784-788, 1982
31. Addington D, Addington J, Schissel B: A depression rating scale for schizophrenics. Schizophrenia Research 3:247-251, 1990
32. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 212:11-19, 1970
33. Guy W: ECDEU Assessment Manual for Psychopharmacology: Revised. DHEW pub no ADM 76-338. Rockville, Md, US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976
34. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13:261-276, 1987
35. Robinson DG, Schooler NR, John M, et al: Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. American Journal of Psychiatry 172:237-248, 2015
36. Mitchell AJ, Delaffon V, Vancampfort D, et al: Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-Analysis of screening practices. Psychological Medicine 42:125-147, 2012